Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Cows ‘milk protein allergy (<jats:styled-content style="fixed-case">CMPA</jats:styled-content>) is the most common food allergy in infants in the United Kingdom. Infants with <jats:styled-content style="fixed-case">CMPA</jats:styled-content> who are not exclusively breastfed require a substitute hypoallergenic formula, which are perceived as having a poor palatability. This study compares the palatability of different extensively hydrolysed formulas (<jats:styled-content style="fixed-case">EHF</jats:styled-content>s) and explores healthcare professional (<jats:styled-content style="fixed-case">HCP</jats:styled-content>) expectations of how palatability impacts infants and their families.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Healthcare professional with experience of <jats:styled-content style="fixed-case">CMPA</jats:styled-content> were recruited to take part in a home palatability test of four <jats:styled-content style="fixed-case">EHF</jats:styled-content>s [Aptamil Pepti 1, Nutricia Ltd. (<jats:styled-content style="fixed-case">EHF</jats:styled-content> W1); Althera, Nestle Health Science (<jats:styled-content style="fixed-case">EHF</jats:styled-content> W2); Similac Alimentum, Abbott (<jats:styled-content style="fixed-case">EHF</jats:styled-content> C1); Nutramigen <jats:styled-content style="fixed-case">LGG</jats:styled-content> 1, Mead Johnson (<jats:styled-content style="fixed-case">EHF</jats:styled-content> C2)] using a blind taste procedure. A randomised, complete block design was used to minimise order and carry‐over biases. Participants completed a questionnaire about the impact of formula palatability on infants and their families.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 100 <jats:styled-content style="fixed-case">HCP</jats:styled-content>s took part (51 dietitians and 49 general practitioners). Overall, whey‐based lactose‐containing <jats:styled-content style="fixed-case">EHF</jats:styled-content>s were ranked the most palatable: <jats:styled-content style="fixed-case">EHF</jats:styled-content> W1 by 77% of participants and <jats:styled-content style="fixed-case">EHF</jats:styled-content> W2 by 20%. <jats:styled-content style="fixed-case">EHF</jats:styled-content> W1 was liked significantly more (<jats:italic>P</jats:italic> < 0.0001) than the other formulas. The vast majority of participants agreed that better palatability would result in an increased chance of non‐rejection (96%), more content families (92%) and decreased healthcare costs (90%).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Amongst <jats:styled-content style="fixed-case">HCP</jats:styled-content>s who manage infants with <jats:styled-content style="fixed-case">CMPA</jats:styled-content>, whey‐based lactose‐containing <jats:styled-content style="fixed-case">EHF</jats:styled-content>s were ranked the most palatable. <jats:styled-content style="fixed-case">HCP</jats:styled-content>s expected that good palatability would result in better acceptance, more content infants and families, alongside decreased wastage and healthcare costs.</jats:p></jats:sec>
Original language | English |
---|---|
Pages (from-to) | 857-862 |
Number of pages | 0 |
Journal | Pediatric Allergy and Immunology |
Volume | 29 |
Issue number | 8 |
DOIs | |
Publication status | Published - Dec 2018 |